Technology ID
TAB-3665
Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection
E-Numbers
E-129-2016-0
Lead Inventor
Gahl, William (National Human Genome Research Institute (NIH/NHGRI))
Co-Inventors
Tifft, Cynthia (National Human Genome Research Institute (NIH/NHGRI))
Rosenzweig, Sergio (Clinical Center (CC))
Adams, David (National Human Genome Research Institute (NIH/NHGRI))
Wolfe, Lynne (National Human Genome Research Institute (NIH/NHGRI))
Applications
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NHGRI
This technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and prevent infections. This is likely related to impaired viral replication and cellular entry. This finding has implications for Ebola and Zika, as well as other viral infections.
Commercial Applications
This finding has implications for Ebola and Zika, as well as other viral infections.
Competitive Advantages
Novel cell line isolation with potential for widespread use.
Licensing Contact: